Well said. There’s a significant near term opportunity ahead with OSA results. This is a multi billion market segment with no pharmacotherapy competition. Resmed commands a +$50 billion MC servicing this space. It’s an absolute monster.
Sure the market is choppy, but that always creates opportunities for shareholders who can see through the noise and spot value. I bought more today and I’m guessing plenty of other long term shareholders did the same.
IHL Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
